arrow
T

Takashi Oshima

nottingham university hospital nhs trust
H指数:39
被引数:5,870

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

ONO-4578 Plus Nivolumab治疗不可切除的局部晚期或复发性胃或胃食管结合部癌

2025-07-060
OAAI
Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer (vol 28, pg 384, 2025)

B淋巴细胞的空间组织与胃癌患者的预后预测(卷28,页384,2025)

2025-05-160
OAAI
Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant chemotherapy and surgical resection

预后营养指数是接受新辅助化疗和手术切除的胰腺癌患者继续S-1辅助化疗的独立危险因素。

2024-12-010
PRE
Neoadjuvant and adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study

新辅助和辅助帕博利珠单抗(pembro)联合化疗(chemo)治疗局部晚期胃或胃食管结合部(G/GEJ)癌:KEYNOTE-585 III期研究的患者报告结局(PROs)

2024-09-010
PRE
Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/ GEJC): FORTITUDE-103 study
2023-11-011
PRE
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
2023-08-151
OA
Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil
2023-05-312
OA